NCT01605396 2019-03-25
MK-8669-064
Merck Sharp & Dohme LLC
Phase 2 Completed
Clinical Trials
5 trialsNCT00759785 2018-08-15
MK-0646-013
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01234857 2017-05-31
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00903006 2015-02-02
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01220570 2015-01-21
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Merck Sharp & Dohme LLC
Phase 1 Completed